Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

cyclin-dependent kinases (CDKs)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (82) Akt (3) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (22) Autophagy (1) Bcl-2 Family (1) Caspase (1) CFTR (1) DYRK (1) ERK (1) FGFR (1) FLT3 (3) GSK-3 (6) HDAC (1) Isotope-Labeled Compounds (1) JAK (1) JNK (2) Ligands for Target Protein for PROTAC (1) P-glycoprotein (1) PARP (1) PKA (1) PKC (3) PROTACs (2) Ser/Thr Protease (2) STAT (4) TOPK (2) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (75) Cardiovascular Disease (3) Infection (4) Inflammation/Immunology (4) Neurological Disease (7)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: CDK Cyclin G-associated Kinase (GAK) CDKL Apical Sodium-Dependent Bile Acid Transporter CaMK PKG SNIPERs DNA-PK VDAC SGLT PDK-1 Pyruvate Oxidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108348

BML-259	CDK	Neurological Disease
BML-259 is a potent cyclin-dependent kinase 5 *(Cdk5)* inhibitor, with IC₅₀s of 64 and 98 nM for Cdk5 and Cdk2, respectively .

HY-163170

FMF-04-159-R	CDK	Cancer
FMF-04-159-R is a cyclin-dependent kinase *CDK14* and *CDK16* inhibitor with IC₅₀ values of 5.9 and 139.1 nM .

HY-114177A

(S)-Ebvaciclib (S)-PF-06873600	CDK	Cancer
(S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase *(CDK)*.

HY-146213

CDK4/6-IN-12	CDK	Cancer
CDK4/6-IN-12 is a potent **cyclin-dependent kinase 4/6 (CDK4/6)** inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC₅₀ of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .

HY-170442

CDK2-IN-37	CDK	Cancer
CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase *(CDK2)* inhibitor with anti-cancer activity .

HY-160941

CDK2-IN-29	CDK	Cancer
CDK2-IN-29 (Compound 13q) is an inhibitor for **cyclin-dependent kinase** (CDK), with IC₅₀ of 96 nM and 360 nM, for CDK 2 and CDK 4, respectively .

HY-162270

CDK2-IN-24	CDK	Cancer
CDK2-IN-24 (compound 3f) is an inhibitor of cyclin-dependent kinase 2 with an elevated binding energy value .

HY-P5428

Cdc2 kinase substrate	CDK	Others
Cdc2 kinase substrate is a biological active peptide. (The native peptide HATPPKKKRK is a substrate for cyclin-dependent protein kinase 1 (CDC2; CDK1).)

HY-162785

XC219	CDK	Infection
XC219 (compound 43) is a cyclin-dependent kinase *CDK) inhibitor, that covalently binds to CDK* active site Lys. XC219 can be used in antifungal research .

HY-151371

CDK8-IN-10	CDK	Cancer
CDK8-IN-10 (compound 2) is a potent, selective **cyclin-dependent kinase (CDK8) inhibitor with an IC₅₀** value of 8.25 nM. CDK8-IN-10 can be used for research of cancer .

HY-169344

CDK7-IN-31	CDK	Cancer
CDK7-IN-31 (compound 13) is a potent and orally active **cyclin-dependent kinase 7 (CDK7) inhibitor with a K_d** value of 0.18 nM. CDK7-IN-31 shows anticancer activity .

HY-108136A

Bisindolylmaleimide X hydrochloride 2 Publications Verification BIM-X hydrochloride; Ro31-8425 hydrochloride	PKC CDK	Cardiovascular Disease
Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective *protein kinase* C (PKC) inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC₅₀** of 200 nM .

HY-124321

Metralindole hydrochloride	CDK	Cancer
Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase *CDK2* and human protein kinase CK2 holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .

HY-124321A

Metralindole	CDK	Cancer
Metralindole is an inhibitor of human cyclin-dependent kinase *CDK2* and human protein kinase CK2 holoenzyme. Metralindole shows good potential as a non-small cell lung cancer inhibitor .

HY-162416

CDK7-IN-27	CDK	Cancer
CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with K_i of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase .

HY-101257A

CDK7-IN-1	CDK	Cancer
CDK7-IN-1, an analog of YKL-5-124, is a cyclin-dependent kinase 7 (cdk7) inhibitor, with an IC₅₀ of less than 100 nM, extracted from patent WO 2016105528 A2, Compound 215 .

HY-19718

OTS964	TOPK CDK Apoptosis	Cancer
OTS964 is an orally active, high affinity and selective TOPK inhibitor with an IC₅₀ of 28 nM . OTS964 is also a potent inhibitor of the cyclin-dependent kinase *CDK11, which binds to CDK11B with a K_d* of 40 nM .

HY-114177

Ebvaciclib 3 Publications Verification PF-06873600	CDK	Cancer
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase *(CDK), with K_i* values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .

HY-112358

GW8510	CDK	Neurological Disease Cancer
GW8510 is a potent **cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2)** inhibitor. GW8510 exhibits neuroprotective and anticancer activities .

HY-123369

BMI-1026	CDK Apoptosis	Cancer
BMI-1026 is a cyclin-dependent kinase 1 (Cdk1) inhibitor with IC₅₀ of 2.3 nM. BMI-1026 induces apoptosis by arresting the G2-M phase .

HY-168057

PROTAC CDK2 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for **cyclin-dependent kinase 2 (CDK2)*. PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC₅₀* of 100-500 nM .

HY-12467

OTS964 hydrochloride 5+ Cited Publications	TOPK CDK Apoptosis	Cancer
OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC₅₀ of 28 nM . OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase *CDK11, which binds to CDK11B with a K_d* of 40 nM .

HY-118902

Aloisine B	CDK	Others
Aloisine B (compound 9) is a cyclin-dependent kinase (CDK) inhibitor. Aloisine B inhibits cell proliferation by arresting cells in both G1 and G2 via competing with ATP-binding pocket .

HY-141687

NSC 107512	CDK Apoptosis	Cancer
NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors .

HY-158377

CDK8/19-IN-2	CDK STAT	Cancer
CDK8/19-IN-2 (compound 12) is an orally active and potent **cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC₅₀** values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research .

HY-N12625

(R)-(+)-O-Demethylbuchenavianine	CDK DYRK GSK-3	Cancer
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC₅₀s of 1.1, 0.95, >10, >10 and >10 μM, respectively .

HY-139342

CDK7-IN-4	CDK	Cancer
CDK7-IN-4 (compound I) is a potent *CDK7* (Cyclin-dependent kinase 7) inhibitor. CDK7-IN-4 shows anticancer activity. CDK7-IN-4 inhibits the in vitro growth of cancer cell lines from a variety of histologies including colon , breast , lung , ovary and stomach , in a dose dependent manner .

HY-176484

CDK9-IN-39	CDK Apoptosis	Cancer
CDK9-IN-39 (1-7a-B1) is an orally active cyclin-dependent kinase 9 (CDK9) inhibitor with an IC₅₀ of 6.51 nM. CDK9-IN-39 induces cell apoptosis by inhibiting the phosphorylation of RNA polymerase II at Ser2 and can be used for study of colorectal cancer .

HY-162683

(S)-PHA533533	CDK	Neurological Disease Cancer
(S)-PHA533533 is a **cyclin-dependent kinase 2 (CDK2)** inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice .

HY-137432A

Avotaciclib trihydrochloride 2 Publications Verification BEY1107 trihydrochloride	CDK Apoptosis	Cancer
Avotaciclib (BEY1107) trihydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib trihydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib trihydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer .

HY-137432B

Avotaciclib hydrochloride 2 Publications Verification BEY1107 hydrochloride	CDK Apoptosis	Cancer
Avotaciclib (BEY1107) hydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib hydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib hydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer .

HY-137432

Avotaciclib 2 Publications Verification BEY1107	CDK Apoptosis	Cancer
Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer .

HY-161847

HZ1	Ser/Thr Protease	Cancer
Anticancer agent 241 (HZ1) is an orally active first-in-class cyclin-dependent kinase like 3 (CDKL3)-specific inhibitor. Anticancer agent 241 shows a strong tumor-suppressing effect, and has the potential to overcome the resistance of CDK4/6 inhibitor .

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent **cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1*, CDK4-cyclin D1, and CDK1-cyclinB* with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .

HY-161709

FLT3/CDKs ligand-1	Ligands for Target Protein for PROTAC FLT3 CDK	Cancer
FLT3/CDKs ligand-1 (Compound 14) is a ligand for target protein, which promotes the degradation of cyclin-dependent kinase (CDK) and the FMS-like tyrosine kinase 3 (FLT3), inhibits FLT3/CDK related proliferations and survivals of leukemia cells. LT3/CDKs ligand-1 can be used for synthesis of PROTAC FLT3/CDKs degrader-1 (HY-161708) .

HY-145394

CDK7-IN-6	CDK	Cancer
CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC₅₀≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer .

HY-145599

Tanuxiciclib	CDK	Cancer
Tanuxiciclib is a **cyclin dependent kinase (CDK)** inhibitor .

HY-145599A

Tanuxiciclib trihydrochloride	CDK	Cancer
Tanuxiciclib trihydrochloride is a **cyclin dependent kinase (CDK)** inhibitor .

HY-116204

SKLB70326	Caspase CDK Apoptosis Bcl-2 Family PARP	Others
SKLB70326 is a small molecule inhibitor of cell cycle progression that induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. SKLB70326 is involved in downregulating cyclin-dependent kinase (CDK) 2, CDK4, and CDK6, while also activating PARP, caspase-3, caspase-9, and Bax, and downregulating Bcl-2.

HY-16462

CDK9-IN-2 5+ Cited Publications	CDK	Cancer
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

HY-16559

Riviciclib hydrochloride 3 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent **cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1*, CDK4-cyclin D1, and CDK1-cyclinB* with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

HY-149261

H1k	Autophagy CDK	Cancer
H1k, a Eudistomin Y derivative, is a lysosome-targeted antiproliferation agent. H1k increases the autophagy signal and downregulate the expression of cyclin-dependent kinase (CDK1) and cyclin B1. H1k can be used in research of cancer .

HY-137432D

Avotaciclib sulfate BEY1107 sulfate	CDK Apoptosis	Cancer
Avotaciclib (BEY1107) sulfate is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib sulfate can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib sulfate can be used in the research of cancer such as pancreatic cancer and lung cancer .

HY-164129

CDK4-IN-3	CDK Apoptosis	Cancer
CDK4-IN-3 (Compound 389) is a potent irreversible cyclin-dependent kinase 4 (CDK4) inhibitor (IC₅₀=25 nM, >10-fold selective over *CDK6). CDK4-IN-3 arrests the cell cycle at G₁ phase, and induces tumor cell apoptosis. CDK*4-IN-3 is promising for research of solid tumors such as breast and lung cancers .

HY-50892

(Rac)-Roscovitine (Rac)-Seliciclib; (Rac)-CYC202	CDK Apoptosis	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
(Rac)-Roscovitine ((Rac)-Seliciclib) is a selective cyclin-dependent kinases (CDKs) inhibitor. (Rac)-Roscovitine binds to the active sites of CDKs competitively with ATP, inhibiting the phosphorylation activity of CDKs. (Rac)-Roscovitine induces apoptosis in cancer cells. (Rac)-Roscovitine is promising for research of cancers or other diseases associated with CDK dysregulation, such as neurodegenerative diseases, cardiac disorders, viral and protozoan infections, glomerulonephritis, and chronic inflammation .

HY-147409

Ulecaciclib	CDK	Cancer
Ulecaciclib is an orally activitive inhibitor of **cyclin-dependent kinase** (CDK), with K_i values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .

HY-173310

CDK2-IN-44	CDK	Cancer
CDK2-IN-44 (Compound 46) is an inhibitor of cyclin-dependent kinase 2 (CDK2). CDK2-IN-44 can effectively inhibit the proliferation of cancer cells and exert its activity in inhibiting cancer cell growth by arresting the cell cycle, promoting Apoptosis, and inducing cellular senescence. CDK2-IN-44 holds promise for use in the research of ovarian cancer and breast cancer .

HY-148868

Akt1&PKA-IN-1	Akt PKA CDK	Others
Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC₅₀ values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) .

HY-145563

Eciruciclib	CDK	Cancer
Eciruciclib is an antineoplastic and potent **cyclin dependent kinase (CDK)** inhibitor .

HY-171787

PPA-037	CDK	Cancer
PPA-037 is an orally active, highly potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12). PPA-037 induces the degradation of cyclin K (Cyclin K), enhancing antiproliferative effects on tumor cells. PPA-037 is promising for research of cancers .

Cat. No.	Product Name	Target	Research Area

HY-P5428

Cdc2 kinase substrate	CDK	Others
Cdc2 kinase substrate is a biological active peptide. (The native peptide HATPPKKKRK is a substrate for cyclin-dependent protein kinase 1 (CDC2; CDK1).)

HY-P1933

[pSer2, pSer5, pSer7]-CTD	Peptides	Cancer
[pSer2, pSer5, pSer7]-CTD, a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD) .

HY-P1933A

[pSer2, pSer5, pSer7]-CTD TFA	CDK	Cancer
[pSer2, pSer5, pSer7]-CTD (TFA), a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12625

(R)-(+)-O-Demethylbuchenavianine	Structural Classification Alkaloids Flavonoids Flavones Other Alkaloids Buchenavia macrophylla Spruce ex Eichler Combretaceae Source classification Plants	CDK DYRK GSK-3
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC₅₀s of 1.1, 0.95, >10, >10 and >10 μM, respectively .

HY-N9561

Vanicoside B 1 Publications Verification	Structural Classification Polygonaceae Source classification Phenols Polyphenols Adiantum venustum Don Plants	CDK STAT
Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks *CDK8*-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis .

Cat. No.	Product Name	Chemical Structure

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cyclin-dependent kinases (CDKs)

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products